Although clinical trials of PRMT5 inhibitors and related MAT2A inhibitors for patients for MTAP-deleted cancers are underway, the frequency, poor outcomes and immune checkpoint inhibitor resistance associated with 9p21.3−/− cancers highlight an urgent need for further therapeutic strategies for this broad class of cancers21,22. Here, PRMT5 is linked to cancer.